Therapeutic interventions such as metformin, an insulin-sensitizing agent, have demonstrated cognitive benefits and reduced AD-related pathology through mechanisms involving improved insulin signaling and reduced neuroinflammation [374,375]. This evidence concerns the gene INS and Alzheimer disease.